Effect of C1-inhibitor in a rat model of necrotizing enterocolitis.

Biol Neonate

Department of Neonatology, Charité, Campus Virchow Hospital, Humboldt University, Berlin, Germany.

Published: October 1999

Our aim was to investigate the effect of C1-inhibitor (C1-INH) in a rat model of necrotizing enterocolitis (NEC). Twenty-four anesthetized and artificially ventilated rats received 0.1 mg/kg endotoxin. Fifteen minutes later, the animals in the study group (n = 12) were treated with 200 IU/kg C1-INH whereas the control animals (n = 12) received normal saline. In all animals, FiO(2) was reduced after 90 min from 0.21 to 0.05 and ventilation continued until 180 min or death. All animals developed shock symptoms. Drop in mean arterial blood pressure was more pronounced and survival time was shorter in the control group. Whereas the C1-INH activity increased in the study group, it decreased in the control group. The extent of macroscopic intestinal lesions did not differ between the groups. In conclusion, C1-INH did not prevent shock, but mitigated and delayed its course.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000014164DOI Listing

Publication Analysis

Top Keywords

rat model
8
model necrotizing
8
necrotizing enterocolitis
8
study group
8
control group
8
c1-inhibitor rat
4
enterocolitis aim
4
aim investigate
4
investigate c1-inhibitor
4
c1-inh
4

Similar Publications

Rats and mice rapidly update timed behaviors.

Anim Cogn

January 2025

Neuroscience Department, Oberlin College, 173 Lorain St, Oberlin, OH, USA.

Keeping track of time intervals is a crucial aspect of behavior and cognition. Many theoretical models of how the brain times behavior make predictions for steady-state performance of well-learned intervals, but the rate of learning intervals in these models varies greatly, ranging from one-shot learning to learning over thousands of trials. Here, we explored how quickly rats and mice adapt to changes in interval durations using a serial fixed-interval task.

View Article and Find Full Text PDF

Pharmacokinetics of Nivolumab and Erythropoietin in a Rat Model of Diet-Induced Obesity.

Pharm Res

January 2025

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ, 08854, USA.

Purpose: To investigate how obesity affects the pharmacokinetics of biologics in a rat model.

Method: Male Long-Evans rats were fed a high-fat diet from the age of 3 weeks and development of obesity was monitored by measuring body size and composition (fat and lean mass). The animals received nivolumab (1 and 8 mg/kg) or recombinant human erythropoietin (rHuEPO, 1000 IU/kg) by intravenous or subcutaneous injection.

View Article and Find Full Text PDF

Persimmon (Diospyros kaki L.) leaves are a traditional medicinal herb used for treating many infectious and inflammatory-related conditions, including wound healing. To validate its traditional use, our study evaluates the acute toxicity and wound-healing effects of methanolic extracts of Persimmon (Diospyros kaki L.

View Article and Find Full Text PDF

The opioid crisis, driven by synthetic opioids like fentanyl, demands innovative solutions. The opioid antidote naloxone has a short action ( ~ 1 hour), requiring repeated doses. To address this, we present a new and simple naloxone prodrug delivery system repurposing a hydrophilic derivative of acoramidis, a potent transthyretin ligand.

View Article and Find Full Text PDF

For individuals at high risk of developing breast cancer, interventions to mitigate this risk include surgical removal of their breasts and ovaries or five years treatment with the anti-estrogen tamoxifen or aromatase inhibitors. We hypothesized that a silicone based anti-estrogen-eluting implant placed within the breast would provide the risk reduction benefit of hormonal therapy, but without the adverse effects that limit compliance. To this end, we demonstrate that when placed adjacent to mammary tissue in the 7,12-dimethylbenz[a]anthracene-induced rat breast cancer model a fulvestrant-eluting implant delays breast cancer with minimal systemic exposure.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!